Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
US Department of Justice
Federal Trade Commission
Medtronic
Boehringer Ingelheim
Julphar
UBS
Farmers Insurance
Cipla
QuintilesIMS

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,685,967

« Back to Dashboard

Summary for Patent: 6,685,967
Title: Methods and compositions for pulmonary delivery of insulin
Abstract:Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.
Inventor(s): Patton; John S. (San Carlos, CA), Foster; Linda (Sunnyvale, CA), Platz; Robert M. (Half Moon Bay, CA)
Assignee: Nektar Therapeutics (San Carlos, CA)
Application Number:08/668,036
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process; Delivery;

Drugs Protected by US Patent 6,685,967

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-001 Jan 27, 2006 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,685,967

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,921,527 Composition for pulmonary administration comprising a drug and a hydrophobic amino acid ➤ Subscribe
5,780,014 Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin ➤ Subscribe
6,019,968 Dispersible antibody compositions and methods for their preparation and use ➤ Subscribe
6,258,341 Stable glassy state powder formulations ➤ Subscribe
5,458,135 Method and device for delivering aerosolized medicaments ➤ Subscribe
6,372,258 Methods of spray-drying a drug and a hydrophobic amino acid ➤ Subscribe
6,303,582 Compositions and methods for nucleic acid delivery to the lung ➤ Subscribe
5,993,783 Method and apparatus for pulmonary administration of dry powder .alpha.1-antitrypsin ➤ Subscribe
6,123,936 Methods and compositions for the dry powder formulation of interferons ➤ Subscribe
6,089,228 Apparatus and methods for dispersing dry powder medicaments ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,685,967

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 9801369 ➤ Subscribe
African Regional IP Organization (ARIPO) 987 ➤ Subscribe
Argentina 013854 ➤ Subscribe
Argentina 042921 ➤ Subscribe
Austria 189124 ➤ Subscribe
Austria 220327 ➤ Subscribe
Austria 245969 ➤ Subscribe
Austria 260688 ➤ Subscribe
Austria 261742 ➤ Subscribe
Austria 264096 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Citi
US Army
Johnson and Johnson
Cipla
Medtronic
McKinsey
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot